ARS Pharmaceuticals (SPRY) said the US Food and Drug Administration approved a lower dosage of neffy for allergic emergencies, including anaphylaxis.
The regulator approved a 1 milligram version of the nasal spray for children 4 years and up, the company said Wednesday in a statement.
A 2 mg version of neffy, an epinephrine nasal spray, was approved in the US in 2024.
ARS shares rose 5.1% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.